Workflow
Terns Pharma (TERN) Investor Presentation - Slideshow
TERNTerns Pharmaceuticals(TERN)2023-01-27 23:51

Obesity • ~30Bmarket5limitedbysupply/costofpeptides•OraldrugsexpectedtoexpandmarketaccesspotentialNASH•Noapproveddrugstodate•Demandfordrugsamenableforco−administration2TernsPipeline:BroadRightstoMultipleWholly−ownedOpportunitiesTargetingSeriousDiseases1.Out−licensedtoHansohPharma(HS10382)intheGreaterChinaregion;Ph1trialongoinginChina;Ternseligibleforupto30B market5limited by supply/cost of peptides • Oral drugs expected to expand market access potential NASH • No approved drugs to date • Demand for drugs amenable for co-administration 2 Terns Pipeline: Broad Rights to Multiple Wholly-owned Opportunities Targeting Serious Diseases 1. Out-licensed to Hansoh Pharma (HS 10382) in the Greater China region; Ph 1 trial ongoing in China; Terns eligible for up to 67M in clinical, regulatory and sales-based milestones, mid single digit percentage royal ...